E.W. Wuis

1.2k total citations
33 papers, 893 citations indexed

About

E.W. Wuis is a scholar working on Infectious Diseases, Molecular Biology and Virology. According to data from OpenAlex, E.W. Wuis has authored 33 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Molecular Biology and 6 papers in Virology. Recurrent topics in E.W. Wuis's work include HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and Analytical Chemistry and Chromatography (6 papers). E.W. Wuis is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and Analytical Chemistry and Chromatography (6 papers). E.W. Wuis collaborates with scholars based in Netherlands, United States and Czechia. E.W. Wuis's co-authors include Y. A. Hekster, P.P. Koopmans, T. B. Vree, David M. Burger, E. J. Ariëns, Eppo van der Kleijn, C.P.W.G.M. Verwey-van Wissen, Patricia W. H. Hugen, E. F. S. Termond and D.M. Burger and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Anesthesiology and Biochemical Pharmacology.

In The Last Decade

E.W. Wuis

32 papers receiving 838 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.W. Wuis Netherlands 16 313 224 191 157 130 33 893
Jan‐Olof Svensson Sweden 22 215 0.7× 104 0.5× 175 0.9× 239 1.5× 36 0.3× 40 1.5k
François Gimenez France 20 147 0.5× 77 0.3× 150 0.8× 111 0.7× 13 0.1× 28 767
Fabienne Péhourcq France 24 108 0.3× 37 0.2× 339 1.8× 244 1.6× 26 0.2× 57 1.5k
Michel Eichelbaum Germany 10 147 0.5× 78 0.3× 53 0.3× 286 1.8× 34 0.3× 12 1.3k
Cheryl L. Zimmerman United States 20 106 0.3× 46 0.2× 58 0.3× 581 3.7× 30 0.2× 63 1.4k
Daisy B. Whigan United States 13 69 0.2× 47 0.2× 202 1.1× 173 1.1× 23 0.2× 22 632
Koteshwara Mudigonda India 20 79 0.3× 25 0.1× 236 1.2× 183 1.2× 48 0.4× 66 1.2k
Donald W. Everett United States 11 130 0.4× 54 0.2× 32 0.2× 162 1.0× 31 0.2× 12 753
Thomas R. MacGregor United States 19 695 2.2× 487 2.2× 43 0.2× 121 0.8× 12 0.1× 46 1.3k
Jeffrey M. Grassi United States 13 131 0.4× 56 0.3× 84 0.4× 90 0.6× 8 0.1× 16 735

Countries citing papers authored by E.W. Wuis

Since Specialization
Citations

This map shows the geographic impact of E.W. Wuis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.W. Wuis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.W. Wuis more than expected).

Fields of papers citing papers by E.W. Wuis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.W. Wuis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.W. Wuis. The network helps show where E.W. Wuis may publish in the future.

Co-authorship network of co-authors of E.W. Wuis

This figure shows the co-authorship network connecting the top 25 collaborators of E.W. Wuis. A scholar is included among the top collaborators of E.W. Wuis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.W. Wuis. E.W. Wuis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burger, D.M., et al.. (2000). Determination of nevirapine, an HIV-1 non nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high perfomance liquid chromatography. Journal of Chromatography B. 744. 64–71. 1 indexed citations
2.
Hugen, Patricia W. H., C.P.W.G.M. Verwey-van Wissen, David M. Burger, et al.. (1999). Simultaious determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.. Journal of Chromatography B. 727. 139–149. 65 indexed citations
3.
Wuis, E.W., et al.. (1999). Stability of dithranol in creams.. Pharmacy World & Science. 21(6). 275–277. 2 indexed citations
4.
Hugen, Patricia W. H., C.P.W.G.M. Verwey-van Wissen, David M. Burger, et al.. (1999). Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 727(1-2). 139–149. 95 indexed citations
5.
Burger, D.M., et al.. (1997). Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B. 703. 235–241. 30 indexed citations
6.
Lucassen, Anneke, et al.. (1997). Successful haemodialysis in sotalol-induced torsade de pointes in a patient with progressive renal failure. Nephrology Dialysis Transplantation. 12(2). 331–333. 3 indexed citations
7.
Burger, D.M., et al.. (1997). Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 703(1-2). 235–241. 51 indexed citations
8.
Ariëns, E. J. & E.W. Wuis. (1994). Chiral Cognisance: A Road to Safer and More Effective Medicinal Products. Journal of the Royal College of Physicians of London. 28(5). 395–398. 1 indexed citations
9.
Vree, T. B., et al.. (1993). Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharmacy World & Science. 15(5). 197–202. 14 indexed citations
10.
Vree, T.B., et al.. (1992). Capacity-limited renal glucuronidation of probenecid by humans. Pharmacy World & Science. 14(5). 325–331. 15 indexed citations
11.
12.
Onghena, Patrick, et al.. (1990). NEU volume 2 issue 4 Cover and Front matter. Acta Neuropsychiatrica. 2(4). f1–f3. 1 indexed citations
13.
Wuis, E.W., et al.. (1990). Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. Pharmacy World & Science. 12(2). 71–74. 28 indexed citations
14.
Vree, T.B., A. M. Baars, & E.W. Wuis. (1990). HPLC analysis and pharmacokinetics of the enantiomers of R,S-oxazepam and R,S-temazepam with their corresponding glucuronide conjugates in urine and plasma of man. Acta Neuropsychiatrica. 2(4). 95–100. 4 indexed citations
15.
Wuis, E.W., et al.. (1990). Determination of a dantrolene metabolite, 5-(p-nitrophenyl)-2-furoic acid, in plasma and urine by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 526(2). 575–580. 4 indexed citations
16.
Wuis, E.W., et al.. (1989). Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. European Journal of Clinical Pharmacology. 37(2). 181–184. 77 indexed citations
17.
Wuis, E.W., et al.. (1989). Whole‐Body Autoradiography of 14C‐Dantrolene in the Marmoset Monkey. Pharmacology & Toxicology. 64(1). 156–158. 13 indexed citations
18.
Wuis, E.W., et al.. (1988). Stereoselectivity of bioactive xenobiotics. Biochemical Pharmacology. 37(1). 9–18. 94 indexed citations
19.
Ariëns, E. J. & E.W. Wuis. (1987). Bias in pharmacokinetics and clinical pharmacology. Clinical Pharmacology & Therapeutics. 42(4). 361–363. 77 indexed citations
20.
Wuis, E.W., et al.. (1987). Rapid simultaneous determination of baclofen and its γ-hydroxy metabolite in urine by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 420(1). 212–216. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan‐Olof Svensson Breakdown of academic impact, for papers by François Gimenez Breakdown of academic impact, for papers by Fabienne Péhourcq Breakdown of academic impact, for papers by Michel Eichelbaum Breakdown of academic impact, for papers by Cheryl L. Zimmerman Breakdown of academic impact, for papers by Daisy B. Whigan Breakdown of academic impact, for papers by Koteshwara Mudigonda Breakdown of academic impact, for papers by Donald W. Everett Breakdown of academic impact, for papers by Thomas R. MacGregor Breakdown of academic impact, for papers by Jeffrey M. Grassi
Rankless by CCL
2026